BioCentury
ARTICLE | Company News

Lantibio in-licenses TRB's Vismed

January 13, 2006 3:13 AM UTC

TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio expe...